. It is unclear if the recent upsurge in EV-D68-associated cases of pneumonia and flaccid paralysis-like illness are due to true changes in EV-D68 disease pathogenesis or improved molecular diagnostics. 13 A previous study from South Africa, using real-time polymerase chain reaction (PCR) assays, identified EVs in 6% (515/8173) of patients that were hospitalized with pneumonia in South Africa. 14 
| MATERIALS AND METHODS

| Study design and population
Study samples were obtained from participants enrolled in a prospective hospital-based surveillance programme for SARI initiated in Africa. The methodology of this study has been described.
14,15
| Sample selection and detection of EV infection
Respiratory specimens (ie nasopharyngeal aspirates for children n=77/327) were randomly selected for genotyping and molecular characterization to obtain 24% of all EV-positive samples per study year.
| Amplification and sequencing of Enteroviruses
The 5′ proximal part of VP1 region was amplified and sequenced, amino acid position 67 to position 133 relative to the start of the VP1 reading frame of the Fermon strain of EV-D68 (AY426531).
Briefly, cDNA synthesis was performed with Transcriptor 1st Strand cDNA Kit (Roche Diagnostics, Mannheim Germany), according to manufacturer's instructions. Primer pairs as described by Nix et al. 16 , 2006 were used. The nested PCR product (375 bp) was analysed on a 1% agarose gel using a 100-bp molecular weight marker (Roche, Mannheim, Germany) as a size reference. Amplicons were purified using the ExoSAP-IT enzyme system (USB Corporation, Cleveland OH, USA) and sequenced using the Big Dye terminator version 3.1 
| Sequencing analysis
Sequence alignments were performed using MAFFT multiple sequence alignment programme. 17 Reference sequences included in the final data set were obtained from GenBank. The Kimura-2 parameter nucleotide substitution model determined as the optimal substitution model using jModelTest was used for the neighbour-joining (NJ) analysis, 18, 19 and the NJ trees were generated using MEGA 5.2 software. 20 For this study, we used the A, B and C strain typing nomenclature to describe diversity of EV-D68 strains. 7,9,10 Sequences of EV-D68 partial VP1
genes generated in this study have been deposited in GenBank with the following accession numbers: KX530500-KX530509. The VP1 nucleotide sequences from EV prototype strains (http://www.picornaviridae.com/enterovirus/enterovirus.htm) used in this study were retrieved from GenBank. The nucleotide sequences for EV-D68 strains were downloaded from GenBank and represent all known clades.
9,10
| Statistical analysis
Differences in characteristics of EV serotypes were assessed using the Fisher's exact test. P-values <.05 were considered to be statistically significant. Analysis was performed using STATA 13 (Stata Corporation, Texas USA).
| Ethical considerations
The SARI protocol was reviewed and approved by the University of 
| RESULTS
| Clinical and epidemiological characteristics of patients hospitalized with enterovirus-associated SARI
During the study period, EV was detected in 8.2% (842/10 260) of SARI cases. For observations with complete data, as displayed in Figure 1 ).
| Enterovirus serotypes and circulation of EV-D68 clades during 2009-2011
Seventeen distinct EV serotypes were identified of which EV-D68 (22%, 10/45) and Echovirus 3 (E3) (11%, 5/45) were the most F I G U R E 3 Molecular characterization of EV-D68 clinical samples based on phylogenetic analysis of nucleotide sequences of the partial VP1 genomic region. Trees were constructed using neighbour-joining methods as implicated in mHg 5 software (http://www.megasoftware. No neurological disease or paralysis symptoms were reported or available for patients from this study who were positive for EV-D68.
Demographic and clinical characteristics of patients in whom EV-D68 were isolated are described in Table 2 . Ages ranged from 3 to 54 months and respiratory symptoms included cough, chest indrawing, breathing difficulty and tachycardia. No amino acid changes in the VP1 region that could lead to increased virulence 21 were observed in the South African samples (results not shown).
| DISCUSSION
We described the EV species circulating among patients from all age groups with SARI in South Africa. During 2009-2011, EV was detected in 8.2% of hospitalized SARI patients, which is within the range reported in other studies (3-25%). [22] [23] [24] Seventeen EV serotypes were identified representing all four EV species. EV-D68 was detected in 22% of EV cases characterized, which compares to frequencies reported in studies from the Netherlands (25%) and Germany Further investigation is needed to determine the disease association of EVs and specifically EV-D68 infection with non-respiratory illness as well as full genome sequencing to determine possible recombination of EV-D68. As this study did not include an asymptomatic control group, we were limited interpreting the attributing causality to enteroviruses in the presence of high-frequency co-infections as well as determining concurrent prevalence in the healthy population.
In conclusion, we showed enteroviruses frequently contributed to SARI in South Africa. A high diversity in the EV species that circulated in South Africa during 2009-2011, EV-D68 specifically circulated at high frequencies among children <5 years of age. EV should be closely monitored to assess the emergence of highly pathogenic strains. There is no vaccine or antiviral available for non-polio EVs. Understanding the contribution of EV serotypes to severe illness will allow for informed decision-making on potential candidate vaccines and development of therapeutic interventions. 
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